Review of NICE Technology Appraisal Guidance No.266; Mannitol dry powder for inhalation for treating cystic fibrosis, and No.276; Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Proposal to incorporate the guidance into a Clinical Guideline

The planned date for review of the above guidance is October 2015 (TA266) and December 2015 (TA276). This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The consideration of a review for these two pieces of guidance has been expedited due to the on-going development of the clinical guideline for cystic fibrosis.

No new evidence has been identified that is likely to lead to a change in the existing Technology Appraisal recommendations.  As a result, we believe that the recommendations from TA266 and TA276 should be incorporated into the ongoing clinical guideline for cystic fibrosis, which is due to be published in February 2017. 

TA266 and TA276 would both be moved to the static list and would remain extant when the guideline is published.  This has the consequence of preserving the funding direction.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.

Please see appendix A for a full list of the organisations we have contacted. 

May 2015

Attachments